Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabili... https://sidneyj394gcz6.blog-gold.com/profile